Cargando…
Characterization of 2 Novel Phosphodiesterase 2 Inhibitors Hcyb1 and PF-05180999 on Depression- and Anxiety-Like Behavior
BACKGROUND: Phosphodiesterase 2A (PDE2A) represents a novel target for new therapies addressing psychiatric disorders. To date, the development of PDE2A inhibitors suitable for human clinical evaluation has been hampered by the poor brain accessibility and metabolic stability of the available compou...
Autores principales: | Yan, Yuqing, Zhao, Yuhan, Lu, Yue, Acharya, Abhinav P, Wang, Wei, Zhan, Chang-Guo, Ye, Jianghong, Du, Fu, Zhu, Xiongwei, Xu, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289143/ https://www.ncbi.nlm.nih.gov/pubmed/37208298 http://dx.doi.org/10.1093/ijnp/pyad020 |
Ejemplares similares
-
Late-Stage Microsomal Oxidation Reduces Drug–Drug
Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189
por: Stepan, Antonia F., et al.
Publicado: (2018) -
The Emerging Role of Phosphodiesterases in Movement Disorders
por: Erro, Roberto, et al.
Publicado: (2021) -
Inhibition of Phosphodiesterase 2 Ameliorates Post-Traumatic Stress–Induced Alcohol Intake Disorder by Regulating cAMP/cGMP Signaling
por: Pan, Xiaoyu, et al.
Publicado: (2022) -
Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2022) -
Phosphodiesterase 10A inhibitor PF-2545920 as a prospective agent for the clinical promotion of sperm motility
por: Yang, Yi-Ting, et al.
Publicado: (2023)